Vertex Pharmaceuticals Inc. has divulged orexin OX2 receptor modulators reported to be useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, narcolepsy, hypersomnia and Parkinson’s disease.
Haisco Pharmaceutical Group Co. Ltd. has identified molecular glue degraders targeting protein cereblon (CRBN) acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
Sage Therapeutics Inc. has synthesized sterol derivatives acting as glutamate receptor ionotropic, NMDA 2A (GRIN2A; GluN2A) negative allosteric modulators reported to be useful for the treatment of neurological disorders.
Helios-Huaming Biopharma Co. Ltd. has described protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cystic fibrosis and asthma, among others.
Exelixis Inc. has divulged membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Chengdu Zeling Biomedical Technology Co. Ltd. has identified bridged pyridazine compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of sepsis.
Scientists at Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical Inc. have synthesized antibody-drug conjugates comprising a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) linked to a cytotoxic drug through a linker and reported to be useful for the treatment of cancer.
Scientists at Beigene Ltd. and Beigene Switzerland GmbH have disclosed antibody-drug conjugates comprising a carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) binding antibody or antigen binding fragments linked to a cytotoxic drug through a linker.
In just its second PCT filing, Ykrita Lifesciences Private Ltd. (YLS) continues to assemble intellectual property for its development of an extracorporeal bioengineered dual-cell liver regeneration (EBDLR) system which serves as a lightweight, portable, ectopic liver device to aid in the rejuvenation of the body’s own liver and treat acute liver failure without the need for surgery.
RSS
